Study wrapper · #1102
Abrupt Smoking Cessation Due to Sensory Aversion Following Tirzepatide Initiation.
Ceesay OI, Rokusek B, Rasmussen J, et al. The primary care companion for CNS disorders. 2026.
DOI: 10.4088/pcc.25cr04174PubMed: 42530904
Editor's note
A single case report noting abrupt smoking cessation linked to sensory aversion after tirzepatide initiation, adding to interest in GLP-1 agents and addictive behaviors. It is an isolated observation and does not establish a reproducible effect.
Plain-language abstract
This case report describes a patient who abruptly stopped smoking due to a sensory aversion that emerged after starting tirzepatide. A single case cannot establish whether the drug reliably produces this effect.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Weak / none
Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.
Obesity pillarsn=——2026